Navigation Links
New Report Puts Spotlight on Epidemic of Painkiller Abuse and Need for Patient Education and Resources
Date:11/10/2011

RICHMOND, Va., Nov. 10, 2011 /PRNewswire/ -- In response to a report recently issued by the Centers for Disease Control and Prevention (CDC) about the rising death toll from prescription painkiller overdose, Reckitt Benckiser Pharmaceuticals Inc. is encouraging individuals affected by painkiller dependence to learn more about the disease of addiction, available options and the importance of getting treatment by visiting www.TurnToHelp.com.

The new CDC report showed that overdose deaths from prescription painkillers such as Vicodin® and OxyContin® now exceeds the number of deaths from heroin and cocaine combined. In fact, the report revealed that on average more than 40 people die each day from overdoses of prescription painkillers representing an annual death toll of more than 15,000 people in the United States.

"Too often I see patients who are reluctant to address their addiction because of fear or embarrassment, without realizing that there are options beyond the traditional rehabilitation facilities and public clinics," said Mark Kraus, Addiction Medicine Specialist and Diplomat of the American Board of Addiction Medicine.  "People dependent on painkillers need to know that treatment can be a private and personalized experience with a physician, who is trained to address an individual's needs."    

Prescription painkiller addiction is a chronic disease. It is not a failure of personal will – a common misconception.  Earlier this year, American Society of Addiction Medicine (ASAM) defined addiction as a chronic brain disorder and not simply a behavioral problem. Currently there are options available in the privacy of a physician's office that are proven to work in conjunction with counseling to help mitigate the unpleasant symptoms experienced by many patients who are working to overcome their dependence.

"Seeking treatment for painkiller dependence can be daunting in part because of misinformation and/or misperceptions about what treatment entails," said Gary Phillips, M.D., President of Reckitt Benckiser Pharmaceuticals, North America. "The truth is that there is a spectrum of options and resources available to people that they may not be aware of, which is why it's important to take that first step and talk to a qualified doctor and get the facts."  

To support people facing addiction to painkillers, the Reckitt Benckiser Pharmaceuticals web site, TurnToHelp.com, offers a simple screening tool to help those at risk recognize if they or a loved one may be addicted and includes a physician finder to identify a local doctor who is specially trained in treating people with addiction to painkillers.

About Reckitt Benckiser Pharmaceuticals

Reckitt Benckiser Pharmaceuticals is a specialty pharmaceutical company committed to expanding access to medical therapies for patients suffering from the chronic, relapsing brain disease of opioid dependence. The company manufactures and markets treatments for opioid dependence. Reckitt Benckiser Pharmaceuticals is a wholly-owned subsidiary of Reckitt Benckiser Group plc, a global company publicly traded on the UK stock exchange.


'/>"/>
SOURCE Reckitt Benckiser Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics Reports 3rd Quarter 2011 Results; YTD Revenues Rise 9%
2. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
3. PDI Reports 2011 Third Quarter Financial Results
4. Emdeon Reports Third Quarter 2011 Results
5. China Kanghui Holdings Reports Third Quarter 2011 Financial Results
6. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
7. Misonix Reports a 14.8% Increase in Revenue for the First Quarter Fiscal 2012 Financial Results
8. Vermillion Reports Results for Third Quarter 2011
9. Unigene Reports Third Quarter 2011 Financial Results
10. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
11. GenVec Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):